Target Information
Recently, Ladder Medical, an innovative leader in China's implanted brain-computer interface (BCI) sector, announced the successful completion of a Series B financing round, raising 350 million RMB. This funding, primarily led by Qiming Venture Partners, aims to expedite clinical trials of its products, develop next-generation technology, and establish a medical-grade MEMS production facility, thereby reinforcing the commercialization of brain-computer interface technology.
This financing marks the largest investment in the history of China's implanted BCI industry. Previously, Ladder Medical had secured hundreds of millions in a Series A funding round as well as tens of millions during its angel round.
Industry Overview in China
Founded in August 2021, Ladder Medical specializes in the research and application of minimally invasive implanted brain-computer interface technologies. Similar to Neuralink, the company has chosen a highly challenging technical path by focusing on invasive brain-computer interfaces and has successfully developed China's first high-throughput implanted brain-computer interface system that complies with medical device standards. This product aims to assist paralyzed patients in performing complex brain-controlled tasks and is the first invasive brain-computer interface product in China to complete registration type testing.
Ladder Medical's project was recognized as part of the
Similar Deals
Qiming Venture Partners → Chengdu Zeling Biotechnology Co., Ltd.
2023
启明创投
invested in
阶梯医疗
in 2023
in a Series B deal
Disclosed details
Transaction Size: $50M